200 related articles for article (PubMed ID: 35759159)
41. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis or advanced liver fibrosis.
Behari J; Gougol A; Wang R; Luu HN; Paragomi P; Yu YC; Molinari M; Chopra K; Malik SM; Geller D; Yuan JM
Hepatol Commun; 2023 Jul; 7(7):. PubMed ID: 37395730
[TBL] [Abstract][Full Text] [Related]
42. Clinical features and management issues of NAFLD-related HCC: what we know so far.
Pugliese N; Alfarone L; Arcari I; Giugliano S; Parigi TL; Rescigno M; Lleo A; Aghemo A
Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):31-43. PubMed ID: 36576057
[TBL] [Abstract][Full Text] [Related]
43. Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States.
Karim MA; Singal AG; Kum HC; Lee YT; Park S; Rich NE; Noureddin M; Yang JD
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):670-680.e18. PubMed ID: 35307595
[TBL] [Abstract][Full Text] [Related]
44. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
[TBL] [Abstract][Full Text] [Related]
45. Epidemiology and risk-stratification of NAFLD-associated HCC.
Ioannou GN
J Hepatol; 2021 Dec; 75(6):1476-1484. PubMed ID: 34453963
[TBL] [Abstract][Full Text] [Related]
46. Alcoholic Liver Disease-Related Hepatocellular Carcinoma: Characteristics and Comparison to General Slovak Hepatocellular Cancer Population.
Šafčák D; Dražilová S; Gazda J; Andrašina I; Adamcová-Selčanová S; Barila R; Mego M; Rác M; Skladaný Ľ; Žigrai M; Janičko M; Jarčuška P
Curr Oncol; 2023 Mar; 30(3):3557-3570. PubMed ID: 36975484
[TBL] [Abstract][Full Text] [Related]
47. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
48. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.
Natarajan Y; Kramer JR; Yu X; Li L; Thrift AP; El-Serag HB; Kanwal F
Hepatology; 2020 Oct; 72(4):1242-1252. PubMed ID: 32022277
[TBL] [Abstract][Full Text] [Related]
49. Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease.
Chhatwal J; Dalgic OO; Chen W; Samur S; Bethea ED; Xiao J; Hur C; Corey KE; Loomba R
JAMA Netw Open; 2022 Sep; 5(9):e2230426. PubMed ID: 36098969
[TBL] [Abstract][Full Text] [Related]
50. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
[TBL] [Abstract][Full Text] [Related]
51. Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B.
Cho H; Chang Y; Lee JH; Cho YY; Nam JY; Lee YB; Lee DH; Cho EJ; Yu SJ; Kim YJ; Lee JM; Yoon JH
J Clin Gastroenterol; 2020 Aug; 54(7):633-641. PubMed ID: 31033805
[TBL] [Abstract][Full Text] [Related]
52. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude.
Pocha C; Kolly P; Dufour JF
Semin Liver Dis; 2015 Aug; 35(3):304-17. PubMed ID: 26378646
[TBL] [Abstract][Full Text] [Related]
53. Should Patients With NAFLD/NASH Be Surveyed for HCC?
Reig M; Gambato M; Man NK; Roberts JP; Victor D; Orci LA; Toso C
Transplantation; 2019 Jan; 103(1):39-44. PubMed ID: 30080818
[TBL] [Abstract][Full Text] [Related]
54. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey.
Tokushige K; Hashimoto E; Horie Y; Taniai M; Higuchi S
J Gastroenterol; 2011 Oct; 46(10):1230-7. PubMed ID: 21748549
[TBL] [Abstract][Full Text] [Related]
55. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
Chan TT; Chan WK; Wong GL; Chan AW; Nik Mustapha NR; Chan SL; Chong CC; Mahadeva S; Shu SS; Lai PB; Chan HL; Wong VW
Am J Gastroenterol; 2020 Jun; 115(6):867-875. PubMed ID: 32149781
[TBL] [Abstract][Full Text] [Related]
56. Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma.
Koh YX; Tan HJ; Liew YX; Syn N; Teo JY; Lee SY; Goh BKP; Goh GBB; Chan CY
J Am Coll Surg; 2019 Nov; 229(5):467-478.e1. PubMed ID: 31398386
[TBL] [Abstract][Full Text] [Related]
57. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease.
Degasperi E; Colombo M
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):156-164. PubMed ID: 28404072
[TBL] [Abstract][Full Text] [Related]
58. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.
Younossi Z; Stepanova M; Ong JP; Jacobson IM; Bugianesi E; Duseja A; Eguchi Y; Wong VW; Negro F; Yilmaz Y; Romero-Gomez M; George J; Ahmed A; Wong R; Younossi I; Ziayee M; Afendy A;
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):748-755.e3. PubMed ID: 29908364
[TBL] [Abstract][Full Text] [Related]
59. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
60. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study.
Chen YG; Yang CW; Chung CH; Ho CL; Chen WL; Chien WC
Hepatol Int; 2022 Aug; 16(4):807-816. PubMed ID: 35064545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
